Coordinatore | UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
Nazionalità Coordinatore | Italy [IT] |
Sito del progetto | http://www.trimage.eu/ |
Totale costo | 8˙000˙040 € |
EC contributo | 5˙994˙380 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2013-INNOVATION-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-12-01 - 2017-11-30 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITA DI PISA
Organization address
address: Lungarno Pacinotti 43/44 contact info |
IT (PISA) | coordinator | 999˙180.00 |
2 |
RS2D SAS
Organization address
address: RUE DES COUTURIERES PARC D'ACTIVITES LES COUTURIERS 24 contact info |
FR (BISCHWILLER) | participant | 1˙703˙200.00 |
3 |
raytest Isotopenmessgeraete GmbH
Organization address
address: Benzstrasse 4 contact info |
DE (Straubenhardt) | participant | 875˙900.00 |
4 |
FORSCHUNGSZENTRUM JUELICH GMBH
Organization address
address: Leo-Brandt-Strasse contact info |
DE (JUELICH) | participant | 566˙100.00 |
5 |
WEEROC SAS
Organization address
address: RUE DES FOSSES 9 contact info |
FR (Corbeil-Essonnes) | participant | 364˙800.00 |
6 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 348˙000.00 |
7 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 285˙600.00 |
8 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 279˙600.00 |
9 |
TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS
Organization address
address: AGIOU SPYRIDONOS 28 KAI MILOU 1 contact info |
EL (AIGALEO) | participant | 223˙400.00 |
10 |
ISTITUTO NAZIONALE DI FISICA NUCLEARE
Organization address
address: Via Enrico Fermi 40 contact info |
IT (FRASCATI) | participant | 219˙000.00 |
11 |
ADVANSID SRL
Organization address
address: VIA SOMMARIVE - FRAZIONE POVO 18 contact info |
IT (TRENTO) | participant | 129˙600.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Schizophrenia is a severe mental disorder that manifests early in life and imposes a high social and economic burden on European societies. An imaging tool that enables the diagnosis of schizophrenia during early development is extremely desirable and is requested by the clinical community in order to make the management of the disease more effective. TRIMAGE aims to optimise and validate an integrated diagnostic solution including simultaneous PET/MR/EEG imaging and specific biomarkers to provide the clinicians an effective tool for the diagnosis and choice of treatment of schizophrenia and other mental health disorders. Specific biomarkers using information from PET/MR, fMRI/EEG and PET/MR/EEG will be used to define the signature of the disease. The imaging hardware will be engineered with the intent of making the instrument a cost-effective and 'beyond the state of the art' commercial product so as to provide a toolset for the diagnosis of patients in most clinical psychiatric centres. The instrument will comprise a 1.5 T cryogen-free, very compact superconducting magnet, a PET insert based on silicon photomultiplier with better performances (2 mm FWHM spatial resolution, 14% sensitivity at the center of the field of view) than any available clinical PET scanner and a fully integrated EEG. The adopted technology will reduce cost, simplify safety management, improve patient comfort and boost performance with respect to state of the art MRI and PET brain imagers. The tool design and construction requires scientific and technological developments in both the physical and medical fields: the work plan counts on the cooperation of highly qualified academic institutions and research centres with a major R&D contribution coming from four high technology European SMEs and Large Companies.'
"Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance"
Read MoreSynaptic mechanisms of memory loss: novel cell adhesion molecules as therapeutic targets
Read MorePREvention of Late Stent Thrombosis by an Interdisciplinary Global European effort
Read More